Group 1 - The board of directors of Wuhan Huirong Biological Technology Co., Ltd. held its 23rd meeting on August 5, 2025, with all five directors present, and the meeting complied with relevant laws and regulations [1] - The board unanimously approved the 2025 semi-annual report, confirming that it accurately reflects the company's operational status without any false statements or omissions [2][3] - The board approved the special report on the use of raised funds, ensuring compliance with relevant regulations and confirming no violations in the management and disclosure of raised funds [2][3] Group 2 - The board proposed a profit distribution plan for the first half of 2025, recommending a cash dividend of 20,157,895.70 yuan (before tax) based on a total share capital of 202,332,557 shares as of June 30, 2025 [2][3] - The profit distribution plan does not require shareholder meeting approval as it was authorized in the 2024 annual shareholder meeting [3] - The board approved the appointment of Han Jie as the rotating general manager, with the term lasting until the end of the current board's term [4] Group 3 - The board approved an investment of 170 million yuan in a project to upgrade veterinary raw material production equipment, aimed at enhancing product quality and increasing production capacity [5] - The company plans to change its registered capital from 179,194,432 yuan to 202,332,557 yuan due to the conversion of convertible bonds into shares, and to relocate its registered address [6] - The board agreed to convene the second extraordinary general meeting of shareholders on August 22, 2025 [6]

Meeting Overview - The third supervisory board meeting of Wuhan Huaneng Biological Technology Co., Ltd. was held on August 5, 2025, with all three supervisors present, complying with relevant laws and regulations [1]. Resolutions Passed - The supervisory board approved the "2025 Half-Year Report" and its summary, confirming that the report accurately reflects the company's situation without any misleading statements or omissions [1][2]. - The board also approved the "Special Report on the Storage and Use of Raised Funds for the First Half of 2025," affirming compliance with regulations regarding the management and disclosure of raised funds [2][3]. - The "Profit Distribution Plan for the First Half of 2025" was approved, ensuring it considers the company's profitability and cash flow without harming minority shareholders' interests [2][3]. - The board approved the investment in a green equipment technological transformation project for veterinary raw materials, aimed at enhancing production capacity and product quality [3].

证券代码：300871 证券简称：回盛生物 公告编号：2025-077 武汉回盛生物科技股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没 有虚假记载、误导性陈述或重大遗漏。 武汉回盛生物科技股份有限公司（以下简称"公司"）于 2025 年 8 月 5 日召开第三届董事会第二十三次会议，审议通过了《关于提请召开公司 2025 年第二次临时股东大会的议案》，并定于 2025 年 8 月 22 日（星期五）14:00 召开 2025 年第二次临时股东大会。现将本次股东大会的相关事项通知如下： 一、召开会议的基本情况 行政法规、部门规章、规范性文件、深圳证券交易所（以下简称"深交所"） 业务规则和《公司章程》等规定。 （1）现场会议召开时间：2025 年 8 月 22 日（星期五）14:00； （2）网络投票时间：2025 年 8 月 22 日，其中，通过深交所交易系统进 行网络投票的具体时间为 2025 年 8 月 22 日 9:15—9:25、9:30—11:30 和 13:00 通过深交所互联网投票系统投票的具体时间为 2025 年 8 月 22 日 9:15 —15:00； —15: ...

Core Viewpoint - The company, Kuaisheng Biological, announced a semi-annual distribution plan for 2025, proposing a cash dividend of 1 yuan per 10 shares, totaling approximately 20.16 million yuan, which represents 17.20% of its net profit, marking the sixth distribution since its listing [2]. Financial Performance - For the first half of 2025, the company reported revenue of 822 million yuan, reflecting a year-on-year increase of 88.45% - The net profit reached 117 million yuan, showing a significant year-on-year growth of 325.88% - Basic earnings per share were recorded at 0.6622 yuan, with a weighted average return on equity of 7.01% [2]. Market Activity - The stock experienced a net inflow of 36.11 million yuan from main funds today, with a total net inflow of 118 million yuan over the past five days [3]. - The latest margin financing balance for the stock is 224 million yuan, which has increased by 24.18 million yuan over the past five days, representing a growth rate of 12.11% [4]. Industry Comparison - In the agricultural, forestry, animal husbandry, and fishery sector, five companies have announced their semi-annual distribution plans for 2025 - Haida Group leads with a cash distribution of 333.27 million yuan, followed by Yisheng Co. and Zhongchong Co. with distributions of 162.78 million yuan and 60.87 million yuan, respectively [4][5].

Core Viewpoint - The company reported significant growth in revenue and net profit for the first half of 2025, indicating a recovery in the animal health sector after a period of decline [1][2]. Financial Performance - The company's revenue for the first half of 2025 was approximately 822 million yuan, an increase of 88.45% year-on-year [1]. - The net profit attributable to shareholders was about 117 million yuan, marking a turnaround from losses with a year-on-year growth of 325.88% [1]. - In Q1 2025, revenue grew by 92.96% and net profit increased by 371.23% [2]. Segment Analysis - Sales revenue from chemical drug formulations increased by 54.23% year-on-year, although the gross margin decreased by 0.36% [1]. - Sales revenue from veterinary raw materials surged by 199.01% year-on-year, with a gross margin improvement of 27.14% [1]. Investment and Expansion Plans - The company plans to invest 170 million yuan in upgrading its veterinary raw material production lines, which will enhance efficiency and reduce costs [2]. - The upgrade will include the introduction of high-efficiency, automated equipment and the addition of fermentation product production lines [2]. Strategic Focus - The company is focusing on vertical integration in the raw material drug industry and horizontal expansion into pet, poultry, ruminant, and aquaculture sectors [3]. - The strategy includes developing new veterinary drugs, optimizing product performance, and expanding into international markets to mitigate domestic cyclical impacts [3].

（文章来源：证券日报） 证券日报网讯 8月5日晚间，回盛生物发布公告称，公司第三届董事会第二十三次会议审议通过了《关 于及其摘要的议案》等多项议案。 ...

回盛生物2025半年报 ...

（文章来源：证券日报） 证券日报网讯 8月5日晚间，回盛生物发布公告称，公司第三届监事会第十五次会议审议通过了《关于 及其摘要的议案》等多项议案。 ...

证券日报网讯8月5日晚间，回盛生物（300871）发布公告称，同意继续聘任韩杰先生为公司轮值总经 理，任期自本次董事会审议通过之日起至第三届董事会届满之日止。 ...

Core Viewpoint - The company, Huibei Huisheng Biological Technology Co., Ltd., a wholly-owned subsidiary of Huisheng Biological (300871.SZ), has approved an investment of 170 million yuan for a green equipment technological transformation project in veterinary raw materials [1] Investment Project Details - The project will be executed in two phases, focusing on upgrading the existing production lines for veterinary raw materials through technological enhancements and equipment optimization [1] - The funding for the project will be sourced from the company's own funds [1] Equipment and Production Enhancements - The project aims to introduce and update high-efficiency, energy-saving, and highly automated equipment, which will enhance the production capacity of existing raw material varieties [1] - New production lines for fermentation products will be added, and measures will be taken to reduce and recycle fermentation waste [1] - Upgrades will also be made to energy storage, air compression, stirring, and wastewater treatment systems to improve energy efficiency and reduce consumption [1] Operational Efficiency - The optimization of the production line equipment composition will ensure that the capacity of upstream and downstream equipment is matched, maximizing production line capacity while reducing energy consumption and lowering labor and maintenance costs [1]